Topic: ESOPRS 2021 ePoster sessions
Time: Sep 17, 2021 16:00 Amsterdam, Berlin, Rome, Stockholm, Vienna, 15:00 London
The zoom session will be a MEETING. Please turn off your camera and mic, unless prompted by the moderators during Q&A. When you enter the meeting there will be 2 BREAKOUT ROOMS. Please choose the appropriate room to join once you have joined the meeting.
The link details are below (you need to be logged in)
You are currently not logged in. If you have an account on this website please login to your account. Not registered yet? Signup here
(plain text version here)
Thyroid Eye Disease-related Interventional Clinical Trials Analysis
Author: Andrew Barton
ePoster Number: 279
Evaluate the prevalence of discontinuation and non-publication among thyroid eye disease-related interventional clinical trials as well as categorizing the allocation of trials to different intervention arms, while differentiating between industry-sponsored and academic-sponsored trials.
We conducted a retrospective, cross-sectional study of thyroid eye disease-related interventional clinical trials in ClinicalTrials.gov dating back to 1993. Fisher’s exact test was performed to uncover any potential associations between funding source and completion.
Only 6 of the 35 included trials (17%) published the results of their study on ClinicalTrials.gov. 26 of the trials (74%) were completed, while 12 trials (34%) were published. 25 trials were academically funded. Among these, 5 were discontinued, while 10 of the completed studies were not published. 10 trials were industry-sponsored. Among these, 2 were discontinued, while 4 of the completed studies were not published. Drugs were the most common intervention type investigated with 29 trials (83%), while devices and procedures accounted for the other 6 trials. 649 participants were enrolled in trials that reached publication while 529 participants were enrolled in unpublished, terminated, or withdrawn trials.
The mandate to register interventional trials with ClinicalTrials.gov has created an opportunity for greater transparency of ophthalmologic research, and more substantial analysis of the allocation and efficient use of resources. The issues of non-completion and non-publication continue to hinder the widespread distribution of clinical trial results. Addressing these issues will ensure a more complete understanding of developing thyroid eye disease-related interventions.
|First name||Last name||Base Hospital / Institution|
|Yash||Vaishnav||Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USA|
|Jamie L.||Schaefer||Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USA|
|Taygan||Yilmaz||Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USA|
Abstract ID: 21-186